In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer.

Abstract

Z-(123)I-MIVE scintigraphy seems to be a useful tool to predict response or resistance to antiestrogen treatment in ER-positive metastatic breast cancer patients and to depict nonresponders before the clinical manifestation of progression.